CHRISTOF VON KALLE
Christof von Kalle studied medicine at the University of Cologne from 1981 to 1987 and earned his doctorate there in hematology/oncology. He specialized in gene therapy during research stays at Memorial Sloan Kettering Cancer Center in New York and at Fred Hutchinson Cancer Research Center in Seattle, and became group leader of the Gene Therapy Program at the University of Freiburg in 1996. Starting in 2002, he served concurrently as professor of pediatrics and program leader of the Gene and Molecular Therapy Program at Cincinnati Children’s Hospital Medical Center in the United States. In 2005 he accepted an appointment as professor of translational oncology at the German Cancer Research Center (DKFZ), where he played a pivotal role in establishing the National Center for Tumor Diseases (NCT), a joint institution of DKFZ and Heidelberg University Hospital. For many years he served as spokesperson of the NCT’s Board of Directors. Since April 2018, he has also held the position of chief research officer at the Sidra Institute for Women and Children’s Health in Doha, Qatar. On June 1, 2019, Professor Christof von Kalle became a tenured professor of clinical translational sciences at the Berlin Institute of Health (BIH) and Charité – Universitätsmedizin Berlin.